Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stride Dystonia
NCT07304089Phase 2Recruiting
- Sponsor
- Vima Therapeutics
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of VIM0423 in dystonia, sponsored by Vima Therapeutics. Started Feb 2026; status: recruiting.
02
Drugs
VIM0423
03
Conditions
dystonia
Beyond the preview
Go deeper on NCT07304089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304089.